An Act relative to promoting comprehensive transparency in the pharmaceutical industry

This bill amends Massachusetts state law to increase transparency within the pharmaceutical industry by adding new definitions and expanding the scope of entities subject to regulation. It specifically includes pharmaceutical manufacturing companies and pharmacy benefit managers in existing reporting and oversight requirements, ensuring they are held accountable alongside other industry players. The legislation also mandates that these companies and managers pay for the state commission's costs in analyzing drug spending trends, with a cap of $2,000 annually per entity. Additionally, the bill requires the inclusion of specific representatives from the pharmaceutical and pharmacy benefit manager sectors in future advisory committees.